ANEBULO PHARMACEUTICALS, INC. Financing Cash Flow
ANEBULO PHARMACEUTICALS, INC. (ANEB) reported Financing Cash Flow of $14.88 million for the 12-month period ending 2025-06-30, per its 10-K filed 2025-09-29.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-02-12
- ANEBULO PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-06-30 was $0.00.
- ANEBULO PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-03-31 was -$116.66K.
- ANEBULO PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2024-06-30 was $0.00.
- ANEBULO PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2024-03-31 was $0.00.
- ANEBULO PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2025 was $14.88M.
- ANEBULO PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2024 was -$62.35K, a 100.98% decline from fiscal 2023.
- ANEBULO PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2023 was $6.38M.
- ANEBULO PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2021 was $21.83M.
| Period end | Net Cash Provided by (Used in) Financing Activities 2 month | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 9 month as first filed | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|---|---|
| 2025-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | -$116.66K derived: sum of 2 quarters · filed 2025-09-29 | $14.88M 10-K · filed 2025-09-29 | |||
| 2025-03-31 | -$116.66K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-13 | $14.88M 10-Q · filed 2025-05-13 | ||||
| 2024-12-31 | $15.00M 10-Q · filed 2026-02-12 | |||||
| 2024-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | $0.00 derived: sum of 2 quarters · filed 2025-09-29 | -$62.35K 10-K · filed 2025-09-29 | |||
| 2024-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-13 | -$62.35K 10-Q · filed 2025-05-13 | ||||
| 2023-12-31 | -$62.35K 10-Q · filed 2025-02-14 | |||||
| 2023-06-30 | -$68.16K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-25 | -$68.16K derived: sum of 2 quarters · filed 2024-09-25 | -$317.08K derived: sum of 3 quarters · filed 2024-09-25 | $6.38M 10-K · filed 2024-09-25 | ||
| 2023-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-15 | -$248.93K derived: sum of 2 quarters · filed 2024-05-15 | $6.45M 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | -$248.93K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-13 | $6.45M 10-Q · filed 2024-02-13 | ||||
| 2022-09-30 | $6.70M 10-Q · filed 2023-11-14 | |||||
| 2021-06-30 | $20.18M derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-09 | $21.83M 10-K · filed 2022-09-09 | ||||
| 2021-03-31 | $1.66M 10-Q · filed 2022-05-11 | $2.05M 10-Q · filed 2021-06-21 | ||||
| 2020-06-30 | $3.18M 10-K · filed 2021-09-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |